Insights and Career Development in Translational Science with Dr. Felix Yeh and Dr. Damon Ng
What’s biomarker research versus biomarker development? How does biomarker play an increasingly important role in current drug discovery efforts? What goes into designing and selecting the best preclinical models to study novel therapeutics? How do we face the challenges for preclinical animal model development when early discovery was already started in the cell models derived from human tissues? If you are interested in these questions and wonder how to venture into these fields, please join us. BATBA invites Dr. Felix Yeh and Dr. Damon Ng to discuss these questions and share their insights and experiences in crafting a successful career in translational science.
Date:10/23/21 (Sat), 4-5 pm
Dr. Felix Yeh, Head of Biomarker, Alector
Dr. Damon Ng, Project Supervisor, Charles River Laboratory
* REGISTRATION REQUIRED. EVENT LINK WILL BE SENT OUT 1HOUR BEFORE START TIME
Q&A LINK(participants are welcome to input your question when setting up before 10/9): https://docs.google.com/spreadsheets/d/1tGwkfFS2_dKv9RZRQ04HRHS3LO_C40rsZlMhyqDdAqM/edit?usp=sharing
EVENT CO-HOST: STANFORD TAIWANESE STUDENT ASSOCIATION
Felix Yeh, PhD currently serves as the Head of Biomarkers at Alector where he leads the development and execution of biomarker strategy for preclinical and Phase I to Phase III clinical programs in immuno-neurology and immuno-oncology. Prior to Alector, Dr. Yeh was a biomarker scientist at Genentech supporting from preclinical stage molecules to Phase II. He served as the therapeutic area lead for neuroinflammation, metabolism and rare diseases. Dr. Yeh is a recognized scientific leader with his research on the role of microglia in neurodegenerative diseases and work on elucidating the pathophysiological processes of disease.
Damon Ng, PhD currently works at Charles River Laboratories, a supervisor for the in-vivo DMPK division at South San Francisco. He collaborates with sponsors from biotech start-ups to big pharmas to enable and facilitate drug discovery and development. His discovery projects focus on pharmacokinetics, pharmacodynamics, and tolerability of test compounds, ranged from small/large molecules, viral vectors, siRNA, and antibodies. He graduated with a neuroscience PhD at the University of Iowa and completed post-doctoral trainings at UC Davis and UC Irvine. His neuroscience research specialized in attention, learning, and memory in rodents and non-human primates, using high-density electrophysiology and chemogenetics.